{
    "deck": {
        "metadata": {
            "title": "ADC Clinical Insights Deck",
            "version": "1.0",
            "theme_key": "clinical_modern"
        },
        "slides": [
            {
                "slide_type": "report_title",
                "layout": "Report Title",
                "body": [
                    {
                        "selection_pane": "report_title_main",
                        "component": "text",
                        "content": "Antibody-Drug Conjugates in the Treatment of Metastatic HR+ BC"
                    },
                    {
                        "selection_pane": "report_title_subtitle",
                        "component": "text",
                        "content": "Virtual – Central | February 4, 2025"
                    },
                    {
                        "selection_pane": "report_title_speaker",
                        "component": "text",
                        "content": "Ruta Rao, MD"
                    },
                    {
                        "selection_pane": "report_title_section",
                        "component": "text",
                        "content": "Results Reportssss"
                    },
                    {
                        "selection_pane": "report_title_bio",
                        "component": "text",
                        "content": "Professor, Department of Internal Medicine, Division of Hematology, Oncology and Cell Therapy, Rush Medical College\nDirector, Coleman Foundation Comprehensive Breast Cancer Clinic\nMedical Director, Rush University Cancer Center"
                    }
                ]
            },
            {
                "slide_type": "meeting_info",
                "title": "MEETING INFORMARION",
                "layout": "Meeting Information",
                "body": [
                    {
                    "selection_pane": "MI_Event_Value",
                    "component": "text",
                    "content": "Activeer® Nanooooo Program: ADCs in the Treatment of HR+ mBC"
                    },
                    {
                    "selection_pane": "MI_Location_Value",
                    "component": "text",
                    "content": "Virtual – Centrallllll"
                    },
                    {
                    "selection_pane": "MI_DateTime_Value",
                    "component": "text",
                    "content": "February 4 | 6:30 PM – 8:30 PM CT"
                    },
                    {
                    "selection_pane": "MI_Moderator_Value",
                    "component": "text",
                    "content": "Ruta Rao, MD"
                    },
                    {
                    "selection_pane": "MI_Attendees_Value",
                    "component": "text",
                    "content": "10 oncologists"
                    },
                    {
                    "selection_pane": "MI_Attendee_Table",
                    "component": "meeting_info_table",
                    "content": "| Institution | # of Attendees |\n|-------------|----------------|\n| Advocateeeeee Lutheran General Hospital | 1 |\n| Beloit Clinic | 1 |\n| Highlands Oncology Group \\| Fayetteville | 1 |\n| Illinois Cancer Specialists | 1 |\n| Mercy Clinic \\| Saint Louis | 1 |\n| Northwest Cancer Center \\| Crown Point | 1 |\n| Oakland University William Beaumont School of Medicine | 1 |\n| Sanford Roger Maris Cancer Center | 1 |\n| Texas Oncology \\| Amarillo | 1 |\n| University of Texas Southwestern Medical Center \\| Dallas | 1 |"
                    },
                    {
                    "selection_pane": "MI_Map",
                    "component": "map",
                    "content": ["TX", "WI", "IL", "MO", "MI", "IN", "AR", "ND"]
                    }
                ]
            },
            {
                "slide_type": "content",
                "title": "Attendee Demographics",
                "layout": "Blank",
                "body": [
                    {
                        "component": "chart",
                        "chartType": "horizontal_bar_chart",
                        "name": "Years Post-Residency Treating Patients With BC",
                        "bucket_label": "Years",
                        "count_label": "Physicians",
                        "aggregations": {
                            "0 to 3": 10,
                            "4 to 6": 0,
                            "7 to 10": 10,
                            "11 to 15": 30,
                            "16 to 20": 30,
                            "21 to 25": 0,
                            ">25": 20
                        }
                    },
                    {
                        "component": "chart",
                        "chartType": "horizontal_bar_chart",
                        "name": "Patient Location:",
                        "bucket_label": "Physicians",
                        "count_label": "Patients",
                        "aggregations": {
                            "1 to 5": 0,
                            "6 to 10": 40,
                            "11 to 20": 50,
                            "21 to 30": 30,
                            "31 to 50": 10,
                            ">50": 20
                        }
                    },
                    {
                        "component": "chart",
                        "chartType": "donut_chart",
                        "name": "Which 1L treatment would you now recommend for this patient with EGFR exon 19 del mNSCLC?",
                        "aggregations": {
                            "Osimertinib + chemotherapy": 44.4,
                            "Amivantamab SQ + lazertinib": 33.3,
                            "Osimertinib monotherapy": 22.2
                        }
                    }
                ]
            },
            {
                "slide_type": "title_only",
                "title": "ADC Safety and Tolerability in HR+/HER2- (HER2-low, HER2-ultralow, and IHC 0) mBC ​",
                "layout": "Title Only"
            },
            {
                "slide_type": "content",
                "title": "ADC Toxicities",
                "layout": "Two Content",
                "body": [
                    {
                        "component": "table",
                        "content": "|  | Toxicitiesssss considered to be more of a concern compared to other ADCs used for mBC |\n|------|--------------------------------------------------------------------------------------------------------------------------------|\n| **T-DXd** | **ILD:** may avoid in patients with preexisting lung conditions or previous pneumonitis, managed with dose reductions<br>**Nausea/vomiting:** managed with antiemetic prophylaxis<br>**Asthenia** |\n| **Dato-DXd** | **Ocular toxicities** (see next slide for more information on management)<br>**Mucositis/stomatitis:** Managed with oral steroid mouthwash qid but the ability to prevent/treat is directly dependent on patient compliance and motivation |\n| **SG** | **Asthenia:** managed with dose reductions<br>**Cytopenias, including neutropenia:** managed with growth factors or dose reductions<br>**Diarrhea:** managed with antidiarrheal regimens or dose reductions<br>**Alopecia:** managed with dose reductions<br>**Weight loss** |",
                        "styles": {
                            "ratio": [
                                0.15,
                                0.85
                            ],
                            "font_size": 16,
                            "header_bg": "#ffffff",
                            "border_color": "#000000",
                            "header_text": "000000",
                            "cell_bg": [
                                "#1A2B5E",
                                "#ffffff",
                                "#F05A28",
                                "#ffffff",
                                "#2BB8B5",
                                "#ffffff"
                            ],
                            "cell_text_color": [
                                "#ffffff",
                                "#000000",
                                "#ffffff",
                                "#000000",
                                "#ffffff",
                                "#000000"
                            ]
                        }
                    },
                    {
                        "component": "list",
                        "content": "- The TROPION-Breast01 safety data for Dato-DXd compared to traditional chemotherapy were notably favored\n\n- Attendees agreed that Dato-DXd had a lower potential for severe side effects observed with other ADCs, such as ILD and severe diarrhea\n\n- The unique toxicities associated with Dato-DXd may pose initial treatment challenges for physicians due to lack of familiarity; however, these toxicities can be effectively managed with more experience\n  - According to one attendee, dry eye is generally more manageable than more severe ocular toxicities (eg, keratitis) observed with other cancer therapies\n  - Effective patient education on ocular toxicities and mucositis requires a multidisciplinary approach involving oncologists, nurses, and pharmacists\n  - Attendees recommended Dato-DXd starter kits with steroid mouthwash and eye drops or integrated EMR prescribing lists to support side effect prevention and management\n\n- SG tolerability is a challenge, commonly requiring dose reductions, lower starting doses, or alternate dosing schedules (Days 1 and 15 instead of Days 1 and 8)\n  - Side effects observed with SG align closely with traditional chemotherapy\n  - One attendee mentioned that oral chemotherapy is better tolerated than SG"
                    }
                ]
            }
        ]
    }
}